21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Zymeworks, BC Cancer Agency, University of Victoria deal

Zymeworks partnered with University of Victoria and BC Cancer Agency to develop cytokine and cytokine receptor pairs as cancer immunotherapy using Zymeworks’ ZymeCAD protein modeling and engineering technology. Zymeworks has an option to further develop...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Bradykinin B1 receptor (BDKRB1; B1R)-targeting PET imaging agent

Imaging TECHNOLOGY: PET A radiolabeled B1R-targeting peptide could be useful as a tumor-targeted PET imaging agent . The agent consisted of a B1R-targeting 10-mer kallidin peptide analog that incorporated non-natural amino acids conjugated to the...
07:00 , Apr 17, 2014 |  BC Innovations  |  Targets & Mechanisms

Unfolding triple-negative breast cancer

A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers-overactivation of the transcription factor X-box binding protein 1 -that could open the door to new therapies for this notoriously...
08:00 , Jan 30, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models High-fidelity prostate cancer xenograft models from fresh patient prostate cancer samples A collection of xenograft mice created using fresh patient prostate...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Qiagen, British Columbia Cancer Agency, Columbia University deal

Qiagen entered two exclusive license agreements for cancer biomarkers that the company plans to use to develop diagnostics. The company licensed worldwide rights from the university to fibroblast growth factor (FGF) receptor ( FGFR )-transforming...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

Takeda, British Columbia Cancer Agency deal

Takeda announced a research partnership with agency to discover and develop cancer targets based on gene analysis. The deal is the first for Takeda's new Shonan Incubation Laboratories program, under which the pharma invites distinguished...
01:04 , Aug 30, 2012 |  BC Extra  |  Company News

Takeda partners with cancer agency

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) announced a research partnership with the British Columbia Cancer Agency to discover and develop cancer targets based on gene analysis. The deal is the first for Takeda's new Shonan Incubation...
07:00 , May 7, 2012 |  BioCentury  |  Emerging Company Profile

Essa: A baby Cougar

Essa Pharma Inc. is developing a next-generation hormone antagonist that blocks a previously intractable androgen receptor domain, a strategy the company expects to work in advanced castration-resistant prostate cancer even after other androgen receptor blockers...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

Verisante Aura regulatory update

Health Canada approved Verisante Aura to aid in assessing skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma. Verisante plans to launch the non-invasive optical system in Canada...